November 29, 2016 - By Linda Rogers · 0 Comments
The stock of Cogentix Medical Incorporated (NASDAQ:CGNT) registered an increase of 18.72% in short interest. CGNT’s total short interest was 76,100 shares in November as published by FINRA. Its up 18.72% from 64,100 shares, reported previously. With 137,400 shares average volume, it will take short sellers 1 days to cover their CGNT’s short positions. The short interest to Cogentix Medical Incorporated’s float is 0.4%. About 36,938 shares traded hands. Cogentix Medical Inc (NASDAQ:CGNT) has risen 83.81% since April 26, 2016 and is uptrending. It has outperformed by 78.55% the S&P500.
Cogentix Medical, Inc. is a global medical device company. The company has a market cap of $102.37 million. The Firm designs, develops, makes and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. It currently has negative earnings. The Firm also offers the Urgent PC Neuromodulation System , a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office treatment of overactive bladder (OAB).
Out of 2 analysts covering Cogentix Medical (NASDAQ:CGNT), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cogentix Medical has been the topic of 3 analyst reports since November 5, 2015 according to StockzIntelligence Inc. Roth Capital upgraded it to “Buy” rating and $3 target price in Thursday, November 5 report. The company was upgraded on Thursday, November 5 by TH Capital. As per Friday, May 6, the company rating was downgraded by Roth Capital.
Cogentix Medical, Inc., incorporated on October 19, 1987, is a global medical device company. The Firm designs, develops, makes and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Firm also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office treatment of overactive bladder (OAB). The Firm also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.
More notable recent Cogentix Medical Inc (NASDAQ:CGNT) news were published by: Prnewswire.com which released: “Cogentix Medical Enters Into Definitive Agreement For $25 Million Equity …” on September 07, 2016, also Prnewswire.com with their article: “Cogentix Medical Shareholders Approve $25 Million Equity Investment” published on November 03, 2016, Prnewswire.com published: “Cogentix Medical Announces Settlement Agreement in Connection with Proxy …” on May 24, 2016. More interesting news about Cogentix Medical Inc (NASDAQ:CGNT) were released by: Prnewswire.com and their article: “Brett Reynolds Rejoins Cogentix Medical As Chief Financial Officer” published on June 15, 2016 as well as Prnewswire.com‘s news article titled: “Darin Hammers Appointed President And CEO Of Cogentix Medical, Inc.” with publication date: July 12, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers